Engineered Therapeutic Proteins
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
39
NCT05704985
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 3, 2023
Completion: Oct 31, 2025
Loading map...